ClinicalTrials.gg
CompletedNCT02757625Updated Dec 17, 2018Results posted

Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit

A Phase 3 interventional study of Dexmedetomidine hydrochloride in ICU Sedation, sponsored by Pfizer. Completed at 12 sites in Japan. Open to participants aged 45 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2018-12-17.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
45 Weeks to 16 Years
Sex
All
01

Study summary

To evaluate the efficacy, safety, and pharmacokinetics of dexmedetomidine given as continuous IV infusion in pediatric subjects [≥ 45 weeks CGA (corrected gestational age) to \<17 years old] requiring sedation under intensive care unit

02

Conditions studied

  • ICU Sedation
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Weeks to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects whose consent is obtained in writing prior to the clinical trial from a guardian after a full explanation. For subjects over 7 years old, it is desirable that an informed assent is also obtained from the pediatric subject him/herself when possible.
  2. Subjects aged ≥45 weeks CGA to \<17 years old at time of consent. No restriction on sex of subject.
  3. [Elective surgical cases] Subjects classified as (ASA) (ASA physical status classification) Class I to III by preoperative diagnosis.
  4. [Elective surgical cases] Subjects who require at least 6 hours of respiratory management with intubation under intensive care from immediately after surgery and are anticipated to require sedation.
  5. [Medical ICU cases] Subjects who require at least 24 hours of respiratory management with intubation under intensive care and are anticipated to require sedation. For medical ICU cases, sedatives used prior to treatment with the product should be discontinued before the start of treatment with the investigational product.
  6. If a subject is a female of , she should not be pregnant or possibly pregnant, or lactating.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are judged by investigator or sub-investigator to have a neurological disease that will make sedation assessment difficult, such as:

    • Subjects with brain damage which is expected to increase intracranial pressure due to trauma or central nervous system disease
    • Subjects with cerebral palsy, autism, severe mental retardation, etc.
    • Subjects with paralysis due to continuous administration of a muscle relaxant or due to a spinal injury of class T5 or higher.
  2. Subjects with 2nd or 3rd degree heart block during the tests at the screening visit (excluding subjects using a pacemaker).
  3. Subjects with any of the following low blood pressure levels during the tests at the screening visit:

    • Age ≥ 45 weeks CGA to \< 1 year old: Systolic Blood Pressure (SBP) \<70 mmHg
    • Age ≥ 1 year old to \< 10 years old: SBP \< 70 + (2 x age in years) mmHg
    • Age ≥ 10 years old to \< 17 years old: SBP \< 90 mmHg
  4. Subject of bradycardia (≤10th centile of heart rate for healthy children) during the physical examination at screening period.
  5. Subjects with ≥100 U/L during the laboratory tests at the screening visit.
  6. Subjects in whom dexmedetomidine or other alfa 2 receptor agonists, alfa 2 receptor antagonists and drug that may be used in this study are .
  7. Subjects who may need a sedative or analgesic (including narcotics) other than dexmedetomidine, midazolam or fentanyl during treatment with the product.
  8. Subjects who have acute febrile illness [with a temperature (core or tympanic) ≥ 38.0°Centigrade] at the screening visit.
  9. Subjects who received other investigational product within 30 days before baseline or subjects who will participate in other study that uses an investigational product during the study period.
  10. Subjects who received dexmedetomidine within 48 hours before baseline.
  11. Subjects who, in the opinion of the investigator or sub-investigator, may be at increased risk to the subject due to the conduct of the study or may have a disease or factor which will probably preclude the obtainment of sufficient study data.
  12. Subjects for whom, in the opinion of the investigator or sub-investigator, risks involved with administration of dexmedetomidine outweigh its benefits (e.g., >2 doses of vasopressor due to cardiogenic shock).
  13. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Sponsor's employees directly involved in the conduct of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    DA-9501

    A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline

    Drug: Dexmedetomidine hydrochloride

Interventions

  • * 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state * 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug

    Percentage of participants who did not require rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and State Behavioral Scale (SBS) (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

Secondary outcomes

  1. Percentage of Participants Who Did Not Require Administration of a Rescue Analgesic Within 24 Hours of Dosing of Study Drug

    Percentage of participants who did not require administration of a rescue analgesic (Fentanyl) in addition to administration of the study drug based on investigator's judgement were reported.

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  2. Total Amount of Rescue Sedative Administered Within 24 Hours of Dosing of Study Drug

    Total amount of rescue sedative (midazolam) administered Within 24 Hours of dosing of study drug.

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  3. Body Weight Adjusted Total Amount (Per Kg) of Rescue Sedative Taken Within 24 Hours of Dosing of Study Drug

    Total amount of rescue sedative (midazolam) required within 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  4. Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug

    Total amount of rescue sedative (fentanyl) required Within 24 Hours of dosing of study drug.

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  5. Body Weight Adjusted Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug

    Total amount of rescue analgesic (fentanyl) within 24 Hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  6. Duration of Maintenance of Target Sedation Level Within 24 Hours of Dosing of Study Drug

    Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the SBS. SBS was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  7. Percentage of Maintenance Duration of Target Sedation Level Within 24 Hours of Dosing of Study Drug

    Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.

    Time frame: From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)

  8. Percentage of Participants Who Did Not Use a Rescue Sedative After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and SBS (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  9. Percentage of Participants Who Did Not Require Dosing of a Rescue Analgesic After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue analgesic (Fentanyl) based on the investigator's judgement were reported.

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  10. Total Amount of Rescue Sedative Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Total amount of rescue sedative (midazolam) administered after 24 hours of dosing of study drug.

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  11. Body Weight Adjusted Total Amount of Rescue Sedative Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Total amount of rescue sedative (midazolam) required after 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  12. Total Amount of Rescue Analgesic Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Total amount of rescue analgesic (Fentanyl) administered by the participants after 24 hours of dosing of study drug.

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  13. Body Weight Adjusted Total Amount of Rescue Analgesic Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Total amount of rescue analgesic (fentanyl) after 24 hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  14. Duration of Maintenance of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more stability and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more stability.

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  15. Percentage of Maintenance Duration of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

    Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.

    Time frame: After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

  16. Duration of Maintenance of Target Sedation Level After Extubation

    Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.

    Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)

  17. Percentage of Maintenance Duration of Target Sedation Level After Extubation

    Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.

    Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)

  18. Total Amount of Rescue Sedative Taken After Extubation

    Total amount of rescue sedative (Midazolam) administered by the participants after extubation.

    Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)

  19. Body Weight Adjusted Total Amount of Rescue Sedative Taken After Extubation

    Total amount of rescue sedative (midazolam) administered by the participants after extubation. Dose was adjusted for body weight (mg divided by kg).

    Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)

  20. Total Amount of Rescue Analgesic Taken After Extubation

    Total amount of rescue analgesic (fentanyl) administered by the participants after extubation.

    Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)

  21. Body Weight Adjusted Total Amount of Rescue Analgesic Taken After Extubation

    Total amount of rescue analgesic (fentanyl) administered by the participants after extubation. Dose was adjusted for body weight (mcg divided by kg).

    Time frame: From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)

  22. Median Time to Conclusion of Mechanical Ventilation

    Time to conclusion of mechanical ventilation was defined as time duration from start of study drug administration until the end of mechanical ventilation.

    Time frame: Baseline (start of study drug dosing) until end of mechanical ventilation (up to 28 days)

Other outcomes

  1. Number of Participants With Treatment- Emergent Adverse Events (AE) and Serious Adverse Events (SAE)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after end of study drug dosing (up to 56 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious adverse events (AEs) and SAEs.

    Time frame: Baseline up to 28 days after end of study drug dosing (up to 56 days)

  2. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs included: systolic and diastolic blood pressure, heart rate, respiratory rate, percutaneous oxygen saturation, end-tidal carbon dioxide, core body temperature and body weight. Criteria for clinically significant vital signs abnormalities was based on Investigators decision.

    Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)

  3. Number of Participants With Laboratory Test Abnormalities

    Criteria for abnormality: hemoglobin, hematocrit and red blood cell count \<0.8\*lower limit of normal(LLN); platelet \<0.5\*LLN; \>1.75\*upper limit of normal(ULN); white blood cell count \<0.6\*LLN; \>1.5\*ULN; lymphocytes, neutrophils and stab cells \<0.8\*LLN; \>1.2\*ULN; eosinophils, basophils and monocytes \>1.2\*ULN; total bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase and gamma guanosine triphosphate and alkaline phosphatase \>3\*ULN; total protein and albumin \<0.8\*LLN; \>1.2\*ULN; glucose \<0.6\*LLN; \>1.5\*ULN; blood urea nitrogen and creatinine \>1.3\*ULN; uric acid \>1.2\*ULN; sodium \<0.95\*LLN; \>1.05\*ULN, potassium, calcium and magnesium \<0.9\*LLN; \>1.1\*ULN; phosphate \<0.8\*LLN; \>1.2\*ULN.

    Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)

  4. Total Input/Output Fluid Volume

    Total input fluid volume was defined as the quantity of total fluids administered and total output fluid volume was defined as the quantity of total fluids excreted or lost during the specified evaluation period.

    Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)

  5. Incidence of Potential Withdrawal Symptoms

    The potential withdrawal symptoms were defined as AEs that occurred or worsened after end of administration of dexmedetomidine. It included bradycardia, abdominal discomfort, abdominal pain, dry mouth, nausea, vomiting, injection site pain, pyrexia, body temperature increased, electrocardiogram QT prolonged, neuralgia, agitation, atelectasis, oropharyngeal pain and hypotension. Incidence of potential withdrawal symptoms was reported in terms of number of participants who had any of the mentioned withdrawal symptoms.

    Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)

  6. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Criteria for clinically significant electrocardiogram abnormalities was based on Investigators decision.

    Time frame: Baseline up to 28 days after end of study drug dosing (Day 56)

07

Results

Posted Dec 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 Years
Started14181912
Completed14181712
Not completed0020
Withdrew: Investigator's discretion0010
Withdrew: Adverse event0010

Outcome measures

PrimaryPercentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug

Percentage of participants who did not require rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and State Behavioral Scale (SBS) (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug
percentage of participantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug78.6 (51.7 to 93.2)66.7 (43.6 to 83.9)78.9 (56.1 to 92.0)91.7 (62.5 to 100.0)77.8 (66.0 to 86.4)
SecondaryPercentage of Participants Who Did Not Require Administration of a Rescue Analgesic Within 24 Hours of Dosing of Study Drug

Percentage of participants who did not require administration of a rescue analgesic (Fentanyl) in addition to administration of the study drug based on investigator's judgement were reported.

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Did Not Require Administration of a Rescue Analgesic Within 24 Hours of Dosing of Study Drug
percentage of participantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Participants Who Did Not Require Administration of a Rescue Analgesic Within 24 Hours of Dosing of Study Drug85.7 (58.8 to 97.2)100.0 (79.3 to 100.0)94.7 (73.5 to 100.0)66.7 (38.8 to 86.4)88.9 (78.5 to 94.8)
SecondaryTotal Amount of Rescue Sedative Administered Within 24 Hours of Dosing of Study Drug

Total amount of rescue sedative (midazolam) administered Within 24 Hours of dosing of study drug.

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Mean · milligrams (mg)
Total Amount of Rescue Sedative Administered Within 24 Hours of Dosing of Study Drug
milligrams (mg)Dexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Total Amount of Rescue Sedative Administered Within 24 Hours of Dosing of Study Drug0.882 ± 0.82823.188 ± 1.69352.469 ± 1.39751.9602.401 ± 1.5793
SecondaryBody Weight Adjusted Total Amount (Per Kg) of Rescue Sedative Taken Within 24 Hours of Dosing of Study Drug

Total amount of rescue sedative (midazolam) required within 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Mean · mg/kg
Body Weight Adjusted Total Amount (Per Kg) of Rescue Sedative Taken Within 24 Hours of Dosing of Study Drug
mg/kgDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Body Weight Adjusted Total Amount (Per Kg) of Rescue Sedative Taken Within 24 Hours of Dosing of Study Drug0.135 ± 0.11600.353 ± 0.22190.142 ± 0.06680.100 ± 00.228 ± 0.1866
SecondaryTotal Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug

Total amount of rescue sedative (fentanyl) required Within 24 Hours of dosing of study drug.

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Mean · micrograms
Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug
microgramsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug91.70 ± 78.772—97.50 ± 081.74 ± 15.75486.84 ± 34.676
SecondaryBody Weight Adjusted Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug

Total amount of rescue analgesic (fentanyl) within 24 Hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Mean · mcg/kg
Body Weight Adjusted Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug
mcg/kgDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Body Weight Adjusted Total Amount of Rescue Analgesic Taken Within 24 Hours of Dosing of Study Drug15.00 ± 9.899—5.00 ± 03.78 ± 1.3117.16 ± 6.789
SecondaryDuration of Maintenance of Target Sedation Level Within 24 Hours of Dosing of Study Drug

Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the SBS. SBS was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Mean · hours
Duration of Maintenance of Target Sedation Level Within 24 Hours of Dosing of Study Drug
hoursDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Duration of Maintenance of Target Sedation Level Within 24 Hours of Dosing of Study Drug7.95 ± 7.1913.89 ± 2.8593.52 ± 5.4952.96 ± 2.0174.50 ± 5.112
SecondaryPercentage of Maintenance Duration of Target Sedation Level Within 24 Hours of Dosing of Study Drug

Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.

Time frame:
From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)
Reported as:
Mean · percentage of time
Percentage of Maintenance Duration of Target Sedation Level Within 24 Hours of Dosing of Study Drug
percentage of timeDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Maintenance Duration of Target Sedation Level Within 24 Hours of Dosing of Study Drug54.08 ± 31.82560.97 ± 28.10450.54 ± 27.89862.25 ± 34.83656.54 ± 29.911
SecondaryPercentage of Participants Who Did Not Use a Rescue Sedative After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue medication for Sedation (Midazolam) based on the data of investigator's judgement and SBS (which was a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation \[placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs\], the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation \[removal of endotracheal tube\], the target sedation depth was -1 to 0, where higher score indicated more responsive) were reported.

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Did Not Use a Rescue Sedative After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
percentage of participantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Participants Who Did Not Use a Rescue Sedative After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation100.0 (29.0 to 100.0)—100.0 (16.7 to 100.0)—100.0 (38.3 to 100.0)
SecondaryPercentage of Participants Who Did Not Require Dosing of a Rescue Analgesic After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Percentage of participants whose period of dosing of the investigational product exceeded 24 hours and who did not received rescue analgesic (Fentanyl) based on the investigator's judgement were reported.

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Did Not Require Dosing of a Rescue Analgesic After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
percentage of participantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Participants Who Did Not Require Dosing of a Rescue Analgesic After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation100.0 (29.0 to 100.0)—100.0 (16.7 to 100.0)—100.0 (38.3 to 100.0)
SecondaryTotal Amount of Rescue Sedative Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Total amount of rescue sedative (midazolam) administered after 24 hours of dosing of study drug.

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

No measurements were reported for this outcome.

SecondaryBody Weight Adjusted Total Amount of Rescue Sedative Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Total amount of rescue sedative (midazolam) required after 24 hours of dosing of study drug. Dose was adjusted for body weight (mg divided by kg).

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

No measurements were reported for this outcome.

SecondaryTotal Amount of Rescue Analgesic Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Total amount of rescue analgesic (Fentanyl) administered by the participants after 24 hours of dosing of study drug.

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

No measurements were reported for this outcome.

SecondaryBody Weight Adjusted Total Amount of Rescue Analgesic Taken After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Total amount of rescue analgesic (fentanyl) after 24 hours of dosing of study drug. Dose was adjusted for body weight (mcg divided by kg).

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)

No measurements were reported for this outcome.

SecondaryDuration of Maintenance of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more stability and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more stability.

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Reported as:
Mean · hours
Duration of Maintenance of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
hoursDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Duration of Maintenance of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation0.81 ± 0.672—0.92 ± 0—0.84 ± 0.479
SecondaryPercentage of Maintenance Duration of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation

Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.

Time frame:
After 24 hours of study drug dosing till end of mechanical ventilation (up to 28 days)
Reported as:
Mean · percentage of time
Percentage of Maintenance Duration of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation
percentage of timeDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Maintenance Duration of Target Sedation Level After 24 Hours of Dosing of Study Drug Till End of Mechanical Ventilation75.00 ± 35.355—100.00 ± 0—83.33 ± 28.868
SecondaryDuration of Maintenance of Target Sedation Level After Extubation

Time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument for intubated participants and its score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= unresponsive. During intubation (placement of a flexible plastic tube into the trachea to maintain an open airway or to serve as a conduit through which to administer certain drugs), the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation (removal of endotracheal tube), the target sedation depth was -1 to 0, where higher score indicated more responsive.

Time frame:
From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Reported as:
Mean · hours
Duration of Maintenance of Target Sedation Level After Extubation
hoursDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Duration of Maintenance of Target Sedation Level After Extubation11.68 ± 11.5897.73 ± 7.5437.60 ± 4.3556.73 ± 5.0368.42 ± 7.679
SecondaryPercentage of Maintenance Duration of Target Sedation Level After Extubation

Percentage of time duration for which the target sedation level was maintained during the specified evaluation period within participants was reported. Target sedation level was analyzed by target sedation scores by using the state behavioral scale (SBS). SBS is a sedation assessment instrument and it's score ranges from 2 to -3, where 2= agitated, 1= restless and difficult to calm, 0= awake and able to calm, -1= responsive to gentle touch or voice, -2= responsive to noxious stimuli and -3= non-responsive. During intubation the target sedation depth by SBS was -2 to 0, where higher score indicated more responsive and after extubation, the target sedation depth was -1 to 0, where higher score indicated more responsive.

Time frame:
From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Reported as:
Mean · Percentage of time
Percentage of Maintenance Duration of Target Sedation Level After Extubation
Percentage of timeDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Percentage of Maintenance Duration of Target Sedation Level After Extubation69.99 ± 28.26053.93 ± 28.61354.45 ± 30.80555.82 ± 41.19558.19 ± 31.829
SecondaryTotal Amount of Rescue Sedative Taken After Extubation

Total amount of rescue sedative (Midazolam) administered by the participants after extubation.

Time frame:
From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Reported as:
Mean · mg
Total Amount of Rescue Sedative Taken After Extubation
mgDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Total Amount of Rescue Sedative Taken After Extubation0.537 ± 0.37410.719 ± 0.33795.994—1.701 ± 2.4148
SecondaryBody Weight Adjusted Total Amount of Rescue Sedative Taken After Extubation

Total amount of rescue sedative (midazolam) administered by the participants after extubation. Dose was adjusted for body weight (mg divided by kg).

Time frame:
From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Reported as:
Mean · mg/kg
Body Weight Adjusted Total Amount of Rescue Sedative Taken After Extubation
mg/kgDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Body Weight Adjusted Total Amount of Rescue Sedative Taken After Extubation0.109 ± 0.09760.072 ± 0.03040.370—0.146 ± 0.1364
SecondaryTotal Amount of Rescue Analgesic Taken After Extubation

Total amount of rescue analgesic (fentanyl) administered by the participants after extubation.

Time frame:
From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Reported as:
Mean · mcg
Total Amount of Rescue Analgesic Taken After Extubation
mcgDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Total Amount of Rescue Analgesic Taken After Extubation——42.90—42.90
SecondaryBody Weight Adjusted Total Amount of Rescue Analgesic Taken After Extubation

Total amount of rescue analgesic (fentanyl) administered by the participants after extubation. Dose was adjusted for body weight (mcg divided by kg).

Time frame:
From extubation till end of treatment (6 hours after start of study drug dosing up to 28 days)
Reported as:
Mean · mcg/kg
Body Weight Adjusted Total Amount of Rescue Analgesic Taken After Extubation
mcg/kgDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Body Weight Adjusted Total Amount of Rescue Analgesic Taken After Extubation——3.00—3.00
SecondaryMedian Time to Conclusion of Mechanical Ventilation

Time to conclusion of mechanical ventilation was defined as time duration from start of study drug administration until the end of mechanical ventilation.

Time frame:
Baseline (start of study drug dosing) until end of mechanical ventilation (up to 28 days)
Reported as:
Median · hours
Median Time to Conclusion of Mechanical Ventilation
hoursDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Median Time to Conclusion of Mechanical Ventilation9.5 (6.3 to 17.5)6.0 (4.6 to 6.3)4.1 (3.0 to 6.0)4.5 (3.8 to 6.0)6.0 (4.8 to 6.2)
Other pre-specifiedNumber of Participants With Treatment- Emergent Adverse Events (AE) and Serious Adverse Events (SAE)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to up to 28 days after end of study drug dosing (up to 56 days) that were absent before treatment or that worsened relative to pretreatment state. AEs included both non-serious adverse events (AEs) and SAEs.

Time frame:
Baseline up to 28 days after end of study drug dosing (up to 56 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment- Emergent Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
AEs1116161255
SAEs00101
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included: systolic and diastolic blood pressure, heart rate, respiratory rate, percutaneous oxygen saturation, end-tidal carbon dioxide, core body temperature and body weight. Criteria for clinically significant vital signs abnormalities was based on Investigators decision.

Time frame:
Baseline up to 28 days after end of study drug dosing (Day 56)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs00000
Other pre-specifiedNumber of Participants With Laboratory Test Abnormalities

Criteria for abnormality: hemoglobin, hematocrit and red blood cell count \<0.8\*lower limit of normal(LLN); platelet \<0.5\*LLN; \>1.75\*upper limit of normal(ULN); white blood cell count \<0.6\*LLN; \>1.5\*ULN; lymphocytes, neutrophils and stab cells \<0.8\*LLN; \>1.2\*ULN; eosinophils, basophils and monocytes \>1.2\*ULN; total bilirubin \>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase and gamma guanosine triphosphate and alkaline phosphatase \>3\*ULN; total protein and albumin \<0.8\*LLN; \>1.2\*ULN; glucose \<0.6\*LLN; \>1.5\*ULN; blood urea nitrogen and creatinine \>1.3\*ULN; uric acid \>1.2\*ULN; sodium \<0.95\*LLN; \>1.05\*ULN, potassium, calcium and magnesium \<0.9\*LLN; \>1.1\*ULN; phosphate \<0.8\*LLN; \>1.2\*ULN.

Time frame:
Baseline up to 28 days after end of study drug dosing (Day 56)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Number of Participants With Laboratory Test Abnormalities1318151157
Other pre-specifiedTotal Input/Output Fluid Volume

Total input fluid volume was defined as the quantity of total fluids administered and total output fluid volume was defined as the quantity of total fluids excreted or lost during the specified evaluation period.

Time frame:
Baseline up to 28 days after end of study drug dosing (Day 56)
Reported as:
Mean · milliliters (mL)
Total Input/Output Fluid Volume
milliliters (mL)Dexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Input Volume779.39 ± 342.617799.18 ± 356.2541023.60 ± 337.8251415.96 ± 822.212979.24 ± 520.514
Output Volume975.06 ± 436.904801.53 ± 353.3791041.80 ± 356.3751313.58 ± 625.4741009.58 ± 461.471
Other pre-specifiedIncidence of Potential Withdrawal Symptoms

The potential withdrawal symptoms were defined as AEs that occurred or worsened after end of administration of dexmedetomidine. It included bradycardia, abdominal discomfort, abdominal pain, dry mouth, nausea, vomiting, injection site pain, pyrexia, body temperature increased, electrocardiogram QT prolonged, neuralgia, agitation, atelectasis, oropharyngeal pain and hypotension. Incidence of potential withdrawal symptoms was reported in terms of number of participants who had any of the mentioned withdrawal symptoms.

Time frame:
Baseline up to 28 days after end of study drug dosing (Day 56)
Reported as:
Count of participants · Participants
Incidence of Potential Withdrawal Symptoms
ParticipantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Bradycardia04004
Abdominal discomfort00101
Abdominal pain00011
Dry mouth00101
Nausea00235
Vomiting11147
Injection site pain00011
Pyrexia10001
Body temperature increased10001
Electrocardiogram QT prolonged00101
Neuralgia00011
Agitation11103
Atelectasis11002
Oropharyngeal pain00011
Hypotension01113
Other pre-specifiedNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Criteria for clinically significant electrocardiogram abnormalities was based on Investigators decision.

Time frame:
Baseline up to 28 days after end of study drug dosing (Day 56)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities00000

Adverse events

Collected over Baseline up to 28 days after end of study drug dosing (Day 56). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexmedetomidine: >=45 Weeks CGA to <12 Months0/14 (0%)0/14 (0%)11/14 (78.6%)
Dexmedetomidine: >=12 Months to <24 Months0/18 (0%)0/18 (0%)16/18 (88.9%)
Dexmedetomidine: >=2 Years to <6 Years0/19 (0%)1/19 (5.3%)16/19 (84.2%)
Dexmedetomidine: >=6 Years to <17 Years0/12 (0%)0/12 (0%)12/12 (100%)
Dexmedetomidine: All Participants0/63 (0%)1/63 (1.6%)55/63 (87.3%)
Most frequent serious events
Most frequent serious events
EventDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
Cardiac tamponadeCardiac disorders0/140/181/190/121/63
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsDexmedetomidine: All Participants
HypotensionVascular disorders3/148/1811/199/1231/63
BradycardiaCardiac disorders6/147/185/192/1220/63
VomitingGastrointestinal disorders1/141/182/195/129/63
NauseaGastrointestinal disorders0/140/182/195/127/63
Respiratory depressionRespiratory, thoracic and mediastinal disorders2/147/183/195/1217/63
AgitationPsychiatric disorders4/142/181/190/127/63
PyrexiaGeneral disorders1/142/181/192/126/63
Body temperature increasedInvestigations1/142/180/190/123/63
Abdominal painGastrointestinal disorders0/140/180/191/121/63
Injection site painGeneral disorders0/140/180/191/121/63

Baseline characteristics

The Full Analysis Set (FAS) included all participants who have received at least one dose of the study drug.

Age, Continuous
Age, Continuous(months)Dexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsTotal
Mean6.1 ± 2.116.9 ± 3.645.7 ± 14.6112.1 ± 37.941.3 ± 41.8
Sex: Female, Male
Sex: Female, Male(Participants)Dexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsTotal
Female877527
Male61112736
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dexmedetomidine: >=45 Weeks CGA to <12 MonthsDexmedetomidine: >=12 Months to <24 MonthsDexmedetomidine: >=2 Years to <6 YearsDexmedetomidine: >=6 Years to <17 YearsTotal
American Indian or Alaska Native00000
Asian1418191263
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

12 sites
  • Asahikawa Medical University Hospital
    Asahikawa, Hokkaido 078-8510, Japan
  • Hyogo Prefectural Kobe Children's Hospital
    Kobe, Hyogo 650-0047, Japan
  • Shikoku Medical Center for Children and Adults
    Zentsuji, Kagawa 765-8507, Japan
  • Osaka Women's and Children's Hospital
    Izumi, Osaka 594-1101, Japan
  • Osaka Medical College Hospital
    Takatsuki, Osaka 569-8686, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 329-0498, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Tokyo Metropolitan Children's Medical Center
    Fuchu, Tokyo 183-8561, Japan
  • University Hospital, Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Okayama University Hospital
    Okayama, 700-8558, Japan
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
  • Shizuoka Children's Hospital
    Shizuoka, 420-8660, Japan
09

References and documents

Publications

  • Takeuchi M, Nemoto S, Suzuki Y, Takahashi N, Takenaka N, Takata A, Kobayashi M. Age-Specific Dose Regimens of Dexmedetomidine for Pediatric Patients in Intensive Care Following Elective Surgery: A Phase 3, Multicenter, Open-Label Clinical Trial in Japan. Pediatr Crit Care Med. 2021 Nov 1;22(11):e546-e557. doi: 10.1097/PCC.0000000000002730. PubMed 33813550 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in May 2017, 10 months.

Results were first posted in Dec 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
May 2, 2016
StartActual
Jul 20, 2016
Primary completionActual
May 24, 2017
CompletionActual
May 24, 2017
Results first posted
Dec 17, 2018
Last update
Dec 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02757625
Lead sponsor
Pfizer
Collaborators
Maruishi Pharmaceutical
Responsible party
Sponsor
First posted
May 2, 2016
Start date
Jul 20, 2016
Primary completion
May 24, 2017
Completion
May 24, 2017
Results posted
Dec 17, 2018
Last update
Dec 17, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion